Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.48 |
| ▸ | CNR2 | P34972 | 12/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14206717 | 0.75 | CNR1 (0.44) | CNR1CNR2EGFRALOX5ADORA3 | |
| SCHEMBL16919139 | 0.71 | ALDH1A1 (0.49) | PIK3C3L3MBTL1KDM4EHSD17B10 | |
| SCHEMBL10394083 | 0.70 | MAPK14 (0.46) | ADORA3MAPK14KDM4E | |
| SCHEMBL5847190 | 0.69 | L3MBTL1 (0.48) | L3MBTL1NPC1 | |
| SCHEMBL6614352 | 0.69 | CNR1 (0.45) | CNR1CNR2EGFRALOX5ADORA3 | |
| SCHEMBL19475136 | 0.69 | GAA (0.45) | PIK3C3L3MBTL1KDM4EHSD17B10 | |
| SCHEMBL2467013 | 0.68 | CNR1 (0.46) | CNR1CNR2EGFRALOX5ADORA3 | |
| SCHEMBL10892245 | 0.67 | RAPGEF4 (0.52) | LMNAHTTSMN1; SMN2L3MBTL1HSD17B10 | |
| SCHEMBL26488151 | 0.66 | PARP14 (0.57) | CNR1CNR2LMNASMN1; SMN2KDM4E | |
| SCHEMBL6352059 | 0.66 | TSHR (0.51) | CNR1CNR2SMN1; SMN2L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656353-B1 | GABANERGIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1656353-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | ROCHE PALO ALTO LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | HTR2C, GABRA2, GABRA4 | CNR1 21/4885CNR2 9/4885EGFR 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.